{"nctId":"NCT01115569","briefTitle":"Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain","startDateStruct":{"date":"2010-05"},"conditions":["Chronic Pain"],"count":424,"armGroups":[{"label":"Hydrocodone Bitartrate","type":"EXPERIMENTAL","interventionNames":["Drug: Hydrocodone Bitartrate"]}],"interventions":[{"name":"Hydrocodone Bitartrate","otherNames":["Hydrocodone Bitartrate Controlled Release (HC-CR)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have a diagnosed moderate to severe chronic pain condition treated with around-the-clock opioids for at least the past 3 months or in the Investigator's opinion qualify for around-the-clock opioid therapy for treatment of their pain\n* Subjects must have been taking opioids at least 5 days/week for the past month at an average daily dose of at least 30 mg hydrocodone\n* Subjects must be able to complete study procedures and attend clinic visits for 6 to 12 months\n* Females subjects of childbearing potential must have a negative urine pregnancy test at the Screen Visit, and must consent to use a medically-acceptable method of contraception throughout the entire study period.\n* Subjects must have had an adequate medical evaluation for the treatment of their underlying painful condition and appropriate primary medical/surgical therapies for the underlying condition\n* Subjects must voluntarily provide written informed consent\n\nExclusion Criteria:\n\n* Any clinically significant condition that would, in the opinion of the investigator, preclude study participation or interfere with the assessment of pain or increase the risk of opioid-related adverse events (AEs)\n* A medical condition that, in the opinion of the Investigator, would compromise the subject's ability to swallow, absorb, metabolize, or excrete study drug\n* A surgical procedure for pain within the last 3 months\n* Uncontrolled blood pressure, i.e., a sitting systolic blood pressure \\>180 mm Hg or \\<90 mm Hg, and/or a sitting diastolic blood pressure \\>120 mm Hg or \\<50 mm Hg at Screening\n* A body mass index (BMI) \\> 45 kg/m2\n* A hospital anxiety and depression scale (HADS) score of \\>12 in either depression or anxiety subscales or an established history of any psychiatric disorder that is poorly controlled\n* A clinically significant abnormality in clinical chemistry, hematology or urinalysis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in Average Daily Pain","description":"Numeric Rating Scale (NRS) for Pain (0-10; where 0 = no pain, 10 = worst pain imaginable) recorded up to 54 weeks, starting at screening through end of study. Lower number equals better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.921","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Maintenance of Efficacy","description":"Clinic Numeric Rating Scale (NRS), Brief Pain Inventory (BPI), Oswestry Disability Index, Hospital Anxiety and Depression Scale, Rescue Doses and Subject Global of Medication","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":638},"commonTop":["Constipation","Nausea","Headache","Somnolence","Vomiting"]}}}